Please use this identifier to cite or link to this item: https://doi.org/10.4049/jimmunol.1102343
Title: Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression
Authors: Zeng, J.
Shahbazi, M.
Wu, C.
Toh, H.C.
Wang, S. 
Issue Date: 1-May-2012
Source: Zeng, J., Shahbazi, M., Wu, C., Toh, H.C., Wang, S. (2012-05-01). Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. Journal of Immunology 188 (9) : 4297-4304. ScholarBank@NUS Repository. https://doi.org/10.4049/jimmunol.1102343
Abstract: Human embryonic stem cell-derived dendritic cells (hESC-DCs) may potentially provide a platform to generate "off-the-shelf" therapeutic cancer vaccines. To apply hESC-DCs for cancer immunotherapy in a semiallogeneic setting, it is crucial for these cells to "jump-start" adaptive antitumor immunity before their elimination by host alloreaction. In this study, we investigated whether CD1d upregulation in hESC-DCs may exploit invariant NKT (iNKT) cell adjuvant activity and boost antitumor immunity. Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upreg-ulated CD1d was functional in presenting α-galactosylceramide for iNKT cell expansion. Pulsed with melanoma Ag recognized by T cell 1 peptide, the CD1d-overexpressing hESC-DCs displayed enhanced capability to prime CD8 + T cells without relying on α-galactosylceramide loading. Blocking the CD1d with Ab reduced the immunogenicity, suggesting the importance of hESC-DC and iNKT cell interaction in this context. The CD1d-overexpressing hESC-DCs also induced a proinflammatory cytokine profile that may favor the T cell priming. Moreover, a similar immunostimulatory effect was observed when the CD1d upregulation strategy was applied in human monocyte-derived dendritic cells. Therefore, our study suggests that the upregulation of CD1d in hESC-DCs provides a novel strategy to enhance their immunogenicity. This approach holds potential for advancing the application of hESC-DCs into human cancer immunotherapy. © 2012 by The American Association of Immunologists, Inc.
Source Title: Journal of Immunology
URI: http://scholarbank.nus.edu.sg/handle/10635/100584
ISSN: 00221767
DOI: 10.4049/jimmunol.1102343
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

9
checked on Jan 10, 2018

WEB OF SCIENCETM
Citations

9
checked on Jan 10, 2018

Page view(s)

25
checked on Jan 15, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.